First-in-human study to evaluate the safety, pharmacokinetics, and pharmacodynamics of RBD4059, a GalNAc-siRNA drug targeting coagulation Factor XI (FXI), in healthy subjects

Effects of a BBB-penetrating oligonucleotide drug, RBD8088, in mouse models of human glioblastoma

First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects

Combination therapy with GalNAc-siRNA drugs targeting PCSK9 and APOC3 resulted in enhanced lipid lowering in humanized ApoC-III mice

RBD7007 a potent GalNAc-siRNA compound for therapeutic reduction of hepatic and circulatory levels of C5

Inhibition of Factor XI using a GalNAc siRNA RBD4059: a novel antithrombotic drug with high potency and long duration